Brief: Esperion Partners With Neopharm To Commercialize Nexletol® (Bempedoic Acid) And Nexlizet® (Bempedoic Acid And Ezetimibe) In Israel

Esperion Therapeutics

12/12/2024 13:03

Dec 12 (Reuters) - Esperion Therapeutics  ESPR.O :
    * ESPERION PARTNERS WITH NEOPHARM TO COMMERCIALIZE NEXLETOL®
(BEMPEDOIC ACID) AND NEXLIZET® (BEMPEDOIC ACID AND EZETIMIBE) IN
ISRAEL
    * ESPERION THERAPEUTICS INC: UNDER TERMS OF AGREEMENT,
ESPERION
WILL RECEIVE AN UPFRONT AND NEAR-TERM MILESTONE PAYMENTS
    * ESPERION THERAPEUTICS INC: UNDER TERMS OF AGREEMENT,
ESPERION
WILL BE ELIGIBLE TO RECEIVE TIERED ROYALTIES ON SALES OF
NEXLETOL/NEXLIZET IN ISRAEL

Source text:  ID:nGNX52X8ZR 
Further company coverage:  ESPR.O 

 ((Reuters.Briefs@thomsonreuters.com;))